Journal article
Atrial remodeling in an ovine model of anthracycline-induced nonischemic cardiomyopathy: Remodeling of the same sort
DH Lau, PJ Psaltis, L MacKenzie, DJ Kelly, A Carbone, M Worthington, AJ Nelson, Y Zhang, P Kuklik, CX Wong, J Edwards, DA Saint, SG Worthley, P Sanders
Journal of Cardiovascular Electrophysiology | Published : 2011
Abstract
Atrial Remodeling in Doxorubicin Cardiomyopathy. Introduction: All preclinical studies of atrial remodeling in heart failure (HF) have been confined to a single model of rapid ventricular pacing. To evaluate whether the atrial changes were specific to the model or represented an end result of HF, this study aimed to characterize atrial remodeling in an ovine model of doxorubicin-induced cardiomyopathy. Methods and Results: Fourteen sheep, 7 with cardiomyopathy induced by repeated intracoronary doxorubicin infusions and 7 controls, were studied. The development of HF was monitored by cardiac imaging and hemodynamic parameters. Open chest electrophysiological study was performed using custom-m..
View full abstractGrants
Awarded by National Heart Foundation of Australia
Funding Acknowledgements
[ "This study was funded in part by a Grant-in-Aid (G08A3646) from the National Heart Foundation of Australia. Dr. Lau is supported by a Medical Postgraduate Scholarship from the National Health and Medical Research Council (NHMRC) of Australia, the Earl Bakken Electrophysiology Scholarship from the University of Adelaide, and a Biomedical Research Scholarship from Kidney Health Australia. Dr. Psaltis is supported by a Medical Postgraduate Scholarship from the NHMRC of Australia and the National Heart Foundation of Australia and Dawes Research Scholarship from the Royal Adelaide Hospital. Dr. Mackenzie is supported by a Peter Doherty Fellowship from the NHMRC of Australia.", "Dr. Sanders is supported by the National Heart Foundation of Australia. Dr. Sanders reports having served on the advisory board of and/or having received lecture fees and research funding from Bard Electrophysiology, Biosense-Webster, Medtronic, St. Jude Medical, Sanofi-aventis, and Merck, Sharp & Dohme. Other authors: No disclosures." ]